1
|
Yamatoya K, Nagai Y, Teramoto N, Kang W, Miyado K, Nakata K, Yagi T, Miyamoto Y. Cryopreservation of undifferentiated and differentiated human neuronal cells. Regen Ther 2022; 19:58-68. [PMID: 35059480 PMCID: PMC8749124 DOI: 10.1016/j.reth.2021.12.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 12/22/2021] [Accepted: 12/23/2021] [Indexed: 12/12/2022] Open
Abstract
The effective use of human-derived cells that are difficult to freeze, such as parenchymal cells and differentiated cells from stem cells, is crucial. A stable supply of damage-sensitive cells, such as differentiated neuronal cells, neurons, and glial cells can contribute considerably to cell therapy. We developed a serum-free freezing solution that is effective for the cryopreservation of differentiated neuronal cells. The quality of the differentiated and undifferentiated SK-N-SH cells was determined based on cell viability, live-cell recovery rate, and morphology of cultured cells, to assess the efficacy of the freezing solutions. The viability and recovery rate of the differentiated SK-N-SH neuronal cells were reduced by approximately 1.5-folds compared to that of the undifferentiated SK-N-SH cells. The viability and recovery rate of the differentiated SK-N-SH cells were remarkably different between the freezing solutions containing 10% DMSO and that containing 10% glycerol. Cryoprotectants such as fetal bovine serum (FBS), antifreeze proteins (sericin), and sugars (maltose), are essential for protecting against freeze damage in differentiated neuronal cells and parenchymal cells. Serum-free alternatives (sericin and maltose) could increase safety during cell transplantation and regenerative medicine. Considering these, we propose an effective freezing solution for the cryopreservation of neuronal cells. The timing of freezing during cell differentiation. More effective serum-free freezing solution for differentiated neuronal cells. Improving the quality of damage-sensitive cells, such as differentiated neuronal cells.
Collapse
|
2
|
Avar M, Heinzer D, Steinke N, Doğançay B, Moos R, Lugan S, Cosenza C, Hornemann S, Andréoletti O, Aguzzi A. Prion infection, transmission, and cytopathology modeled in a low-biohazard human cell line. Life Sci Alliance 2020; 3:3/8/e202000814. [PMID: 32606072 PMCID: PMC7335386 DOI: 10.26508/lsa.202000814] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 06/19/2020] [Accepted: 06/19/2020] [Indexed: 12/19/2022] Open
Abstract
Expanding the toolbox of prion research to a low-biohazard, scalable human cell model. Transmission of prion infectivity to susceptible murine cell lines has simplified prion titration assays and has greatly reduced the need for animal experimentation. However, murine cell models suffer from technical and biological constraints. Human cell lines might be more useful, but they are much more biohazardous and are often poorly infectible. Here, we describe the human clonal cell line hovS, which lacks the human PRNP gene and expresses instead the ovine PRNP VRQ allele. HovS cells were highly susceptible to the PG127 strain of sheep-derived murine prions, reaching up to 90% infected cells in any given culture and were maintained in a continuous infected state for at least 14 passages. Infected hovS cells produced proteinase K–resistant prion protein (PrPSc), pelletable PrP aggregates, and bona fide infectious prions capable of infecting further generations of naïve hovS cells and mice expressing the VRQ allelic variant of ovine PrPC. Infection in hovS led to prominent cytopathic vacuolation akin to the spongiform changes observed in individuals suffering from prion diseases. In addition to expanding the toolbox for prion research to human experimental genetics, the hovS cell line provides a human-derived system that does not require human prions. Hence, the manipulation of scrapie-infected hovS cells may present fewer biosafety hazards than that of genuine human prions.
Collapse
Affiliation(s)
- Merve Avar
- Institute of Neuropathology, University of Zurich, Zurich, Switzerland
| | - Daniel Heinzer
- Institute of Neuropathology, University of Zurich, Zurich, Switzerland
| | - Nicolas Steinke
- Institute of Neuropathology, University of Zurich, Zurich, Switzerland
| | - Berre Doğançay
- Institute of Neuropathology, University of Zurich, Zurich, Switzerland
| | - Rita Moos
- Institute of Neuropathology, University of Zurich, Zurich, Switzerland
| | - Severine Lugan
- UMR INRA/ENVT 1225 IHAP, École Nationale Vétérinaire de Toulouse (ENVT), Toulouse, France
| | - Claudia Cosenza
- UMR INRA/ENVT 1225 IHAP, École Nationale Vétérinaire de Toulouse (ENVT), Toulouse, France
| | - Simone Hornemann
- Institute of Neuropathology, University of Zurich, Zurich, Switzerland
| | - Olivier Andréoletti
- UMR INRA/ENVT 1225 IHAP, École Nationale Vétérinaire de Toulouse (ENVT), Toulouse, France
| | - Adriano Aguzzi
- Institute of Neuropathology, University of Zurich, Zurich, Switzerland
| |
Collapse
|
3
|
Keckler M, Anderson K, McAllister S, Rasheed J, Noble-Wang J. Development and implementation of evidence-based laboratory safety management tools for a public health laboratory. SAFETY SCIENCE 2019; 117:205-216. [PMID: 31156293 PMCID: PMC6537614 DOI: 10.1016/j.ssci.2019.04.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
We developed an evidence-based continuous quality improvement (CQI) cycle for laboratory safety as a method of utilizing survey data to improve safety in a public health laboratory setting. • Expert Opinion: The CQI cycle begins with the solicitation of laboratory staff input via an annual survey addressing potential chemical, physical and radiological hazards associated with multiple laboratory activities. The survey collects frequency, severity and exposure data related to these activities in the context of the most pathogenic organisms handled at least weekly. • Gap Analysis: Step 2 of the CQI cycle used survey data to identify areas needing improvement. Typically, the traditional two-dimensional risk assessment matrix is used to prioritize mitigations. However, we added an additional dimension - frequency of exposure - to create three-dimensional risk maps to better inform and communicate risk priorities. • Mitigation Measures: Step 3 of the CQI cycle was to use these results to develop mitigations. This included evaluating the identified risks to determine what risk control measures (elimination, substitution, engineering, administrative or PPE) were needed. In the 2016 iteration of the CQI cycle described here, all mitigations were based on administrative controls. • Evaluation and Feedback: The last step of the CQI cycle was to evaluate the inferred effects of interventions through subsequent surveys, allowing for qualitative assessment of intervention effectiveness while simultaneously restarting the cycle by identifying new hazards. Here we describe the tools used to drive this CQI cycle, including the survey tool, risk analysis method, design of interventions and inference of mitigation effectiveness.
Collapse
Affiliation(s)
- M.S. Keckler
- Centers for Disease Control and Prevention, National Center for Emerging Zoonotic and Infectious Diseases, Division of Healthcare Quality Promotion, Clinical and Environmental Microbiology Branch, United States
- Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology and Laboratory Services, Laboratory Leadership Service Fellowship, United States
| | - K. Anderson
- Centers for Disease Control and Prevention, National Center for Emerging Zoonotic and Infectious Diseases, Division of Healthcare Quality Promotion, Clinical and Environmental Microbiology Branch, United States
| | - S. McAllister
- Centers for Disease Control and Prevention, National Center for Emerging Zoonotic and Infectious Diseases, Division of Healthcare Quality Promotion, Clinical and Environmental Microbiology Branch, United States
| | - J.K. Rasheed
- Centers for Disease Control and Prevention, National Center for Emerging Zoonotic and Infectious Diseases, Division of Healthcare Quality Promotion, Clinical and Environmental Microbiology Branch, United States
| | - J. Noble-Wang
- Centers for Disease Control and Prevention, National Center for Emerging Zoonotic and Infectious Diseases, Division of Healthcare Quality Promotion, Clinical and Environmental Microbiology Branch, United States
| |
Collapse
|
4
|
Zur Hausen H, Bund T, de Villiers EM. Infectious Agents in Bovine Red Meat and Milk and Their Potential Role in Cancer and Other Chronic Diseases. Curr Top Microbiol Immunol 2019; 407:83-116. [PMID: 28349283 DOI: 10.1007/82_2017_3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Red meat and dairy products have frequently been suggested to represent risk factors for certain cancers, chronic neurodegenerative diseases, and autoimmune and cardiovascular disorders. This review summarizes the evidence and investigates the possible involvement of infectious factors in these diseases. The isolation of small circular single-stranded DNA molecules from serum and dairy products of Eurasian Aurochs (Bos taurus)-derived cattle, obviously persisting as episomes in infected cells, provides the basis for further investigations. Gene expression of these agents in human cells has been demonstrated, and frequent infection of humans is implicated by the detection of antibodies in a high percentage of healthy individuals. Epidemiological observations suggest their relationship to the development multiple sclerosis, to heterophile antibodies, and to N-glycolylneuraminic acid (Neu5Gc) containing cell surface receptors.
Collapse
Affiliation(s)
- Harald Zur Hausen
- Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
| | - Timo Bund
- Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | | |
Collapse
|
5
|
Simmons M, Ru G, Casalone C, Iulini B, Cassar C, Seuberlich T. DISCONTOOLS: Identifying gaps in controlling bovine spongiform encephalopathy. Transbound Emerg Dis 2017; 65 Suppl 1:9-21. [PMID: 28795509 DOI: 10.1111/tbed.12671] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Indexed: 11/29/2022]
Abstract
This article summarizes the 2016 update of the DISCONTOOLS project gap analysis on bovine spongiform encephalopathy (BSE), which was based on a combination of literature review and expert knowledge. Uncertainty still exists in relation to the pathogenesis, immunology and epidemiology of BSE, but provided that infected material is prohibited from entering the animal feed chain, cases should continue to decline. BSE does not appear to spread between cattle, but if new strains with this ability appear then control would be considerably more difficult. Atypical types of BSE (L-BSE and H-BSE) have been identified, which have different molecular patterns and pathology, and do not display the same clinical signs as classical BSE. Laboratory transmission experiments indicate that the L-BSE agent has zoonotic potential. There is no satisfactory conclusion regarding the origin of the BSE epidemic. C-BSE case numbers declined rapidly following strict controls banning ruminant protein in animal feed, but occasional cases still occur. It is unclear whether these more recent cases indicate inadequate implementation of the bans, or the possibility that C-BSE might occur spontaneously, as has been postulated for H- and L-BSE. All of this will have implications once existing bans and levels of surveillance are both relaxed. Immunochemical tests can only be applied post-mortem. There is no immunological basis for diagnosis in the live animal. All aspects of disease control are expensive, particularly surveillance, specified risk material removal and feed controls. There is pressure to relax feed controls, and concurrent pressure from other sources to reduce surveillance. While the cost benefit argument can be applied successfully to either of these approaches, it would be necessary to maintain the ban on intraspecies recycling and some baseline surveillance. However, the potential risk is not limited to intraspecies recycling; recycling with cross-species transmission may be an ideal way to select or/and modify properties of transmissible spongiform encephalopathies agents in the future.
Collapse
Affiliation(s)
- M Simmons
- OIE, National and EU Reference Laboratory for BSE and Scrapie, Department of Pathology, APHA Weybridge, Addlestone, Surrey, UK
| | - G Ru
- CEA - National Reference Laboratory for Transmissible Spongiform Encephalopathies, OIE Reference Laboratories for BSE and Scrapie, Unit of Biostatistics, Epidemiology and Risk Analysis, Istituto Zooprofilattico Sperimentale del Piemonte, Turin, Italy
| | - C Casalone
- CEA - National Reference Laboratory for Transmissible Spongiform Encephalopathies, OIE Reference Laboratories for BSE and Scrapie, Neuropathology Laboratory, Istituto Zooprofilattico Sperimentale del Piemonte, Turin, Italy
| | - B Iulini
- CEA - National Reference Laboratory for Transmissible Spongiform Encephalopathies, OIE Reference Laboratories for BSE and Scrapie, Neuropathology Laboratory, Istituto Zooprofilattico Sperimentale del Piemonte, Turin, Italy
| | - C Cassar
- OIE, National and EU Reference Laboratory for BSE and Scrapie, Department of Pathology, APHA Weybridge, Addlestone, Surrey, UK
| | - T Seuberlich
- NeuroCenter, OIE and National Reference Laboratories for BSE and Scrapie, Division of Neurological Sciences, Vetsuisse Faculty, Bern, Switzerland
| |
Collapse
|
6
|
Bistaffa E, Rossi M, De Luca CMG, Moda F. Biosafety of Prions. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2017; 150:455-485. [PMID: 28838674 DOI: 10.1016/bs.pmbts.2017.06.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Prions are the infectious agents that cause devastating and untreatable disorders known as Transmissible Spongiform Encephalopathies (TSEs). The pathologic events and the infectious nature of these transmissible agents are not completely understood yet. Due to the difficulties in inactivating prions, working with them requires specific recommendations and precautions. Moreover, with the advent of innovative technologies, such as the Protein Misfolding Cyclic Amplification (PMCA) and the Real Time Quaking-Induced Conversion (RT-QuIC), prions could be amplified in vitro and the infectious features of the amplified products need to be carefully assessed.
Collapse
Affiliation(s)
- Edoardo Bistaffa
- IRCCS Foundation Carlo Besta Neurological Institute, Milan, Italy; Scuola Internazionale Superiore di Studi Avanzati (SISSA), Trieste, Italy
| | - Martina Rossi
- Scuola Internazionale Superiore di Studi Avanzati (SISSA), Trieste, Italy
| | - Chiara M G De Luca
- IRCCS Foundation Carlo Besta Neurological Institute, Milan, Italy; Università degli Studi di Pavia, Pavia, Italy
| | - Fabio Moda
- IRCCS Foundation Carlo Besta Neurological Institute, Milan, Italy.
| |
Collapse
|